Global Herpes Zoster Drug Market has High Potential for Growth

  • Increase in exposure to ultraviolet radiations and harmful chemicals is boosting the market growth.
  • Global herpes zoster drug market is highly fragmented.
  • Rising awareness among people about the herpes zoster and its treatment is acting as a catalyst to market growth.

Global herpes zoster drug market is growing at a healthy CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing exposure to ultraviolet radiation which may suppress the cell-mediated immunity, which is a major factor responsible for the growing incidence of herpes zoster and patients being treated for cancer and affected with advanced HIV infection are at a greater risk of developing herpes zoster, which is expected to boost the growth of the global herpes zoster drug market.

The key market players in the global herpes zoster drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Merck & Co., Inc, Pfizer Inc, AstraZeneca, Abbott, Astellas Pharma Inc, NAL Pharma, TSRL, Inc, GeneOne Life Science, Beijing Minhai Biotechnology Co., Ltd, Foamix Pharmaceuticals Ltd, Maruho Co.,Ltd., Sinovac Biotech Ltd, Hepion Pharmaceuticals, CELGENE CORPORATION and others.

Get Sample Analysis of Global Market Information

Market Definition

Herpes zoster also known as shingles, it is a viral infection, characterized by a painful rashes over the skin, rashes can occur anywhere on the body but it most commonly appears as a single stripe of blisters on the abdomen or backside of the body. Herpes zoster is caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox. Older adults and individuals with weak immune system are at greater risk of having herpes zoster. Signs and symptoms include one-sided stabbing pain, headache, tingling, itching, nausea, body aches, and fluid-filled blistering red rash, typically on the abdomen or face.

Older adults and individuals with weak immune system are at greater risk of having herpes zoster.

According to the Centers for disease control and prevention, US the annual incidence rate of herpes zoster in US population is approximately 4 cases per 1,000 persons. The annual incidence rate among people 60 years of age and older is about 10 cases per 1,000 US populations. There are one million estimated cases of herpes zoster in the United States annually. Increasing exposure of ultraviolet radiation and certain chemical substances which deteriorates the immunity system acts as a major contributing factor for the incidence of herpes zoster.

Market Drivers

  • Increase in exposure to ultraviolet radiations and harmful chemicals is boosting the market growth
  • Increasing prevalence of cancer and HIV infection is driving the market growth
  • Vulnerable aging population as they highly prone to herpes zoster viral infection can also act as a market driver
  • Rising awareness among people about the herpes zoster and its treatment is acting as a catalyst to market growth

Market Restraints

  • Low healthcare expenditure in developing regions is hampering the market growth
  • High cost of antibodies is restraining vaccination drive in developing economies
  • Weak pipeline for herpes zoster is restraining the market growth
  • High cost-containment measures undertaken by governments along with the ongoing healthcare reforms are hampering the market growth.

Get TOC of Full Report

Herpes zoster is caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.

Key Developments

  • In May 2019, GlaxoSmithKline plc is developing herpes zoster subunit vaccine (GSK1437173A) for the treatment of herpes zoster (shingles). This vaccine is currently under phase lll clinical trial. It will be indicated for the prevention of herpes zoster (shingles) in adults aged 50 years and older. Currently available vaccines are contraindicated in specific subgroups of people, but this vaccine has a potential to provide long-term immunogenicity to all groups of people
  • In October 2017, GlaxoSmithKline plc received the US FDA approval for Shingrix vaccine for the treatment of herpes zoster. Shingrix is a zoster vaccine recombinant, adjuvanted vaccine against the virus that causes herpes zoster. Shingrix is specifically indicated for the prevention of herpes zoster (shingles) in adults aged 50 years and older and post-herpetic neuralgia (long-lasting nerve pain following shingles)

Competitive Analysis:

Global herpes zoster drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of herpes zoster drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Only $1/click

Submit Your Ad Here

Rashi Pande

About Us Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. 
https://www.databridgemarketresearch.com/

Leave a Reply